Patients with Ulcerative Colitis (UC) often have a persistent inflammation at the mucosal level indicating an unstable disease status, which likely provokes new flare ups of the disease.
Alfa® can reduce this inflammation after 4-8 weeks of treatment!
Alfa® has shown to be very effective in the control of growth and number of sporadic polyps - a further secondary opportunity of significant market size.